Tiziana Life Sciences Ltd (TLSA)
Last Price$1.1(2.7%)
Market Cap$109.6M
TLSA Rating
TLSA Quality rating performance
TLSA Intrinsic Value
Key Highlights:
As of Mar 24, 2025 TLSA Relative Value is $1.0, which is overvalued by 8.4%, compared to current share price of $1.1.
As of Mar 24, 2025 TLSA DCF Value is N/A, which is undervalued by N/A, compared to current share price of $1.1.
TLSA Share Price History
1W (30.3%)
1M 19.3%
6M 17.4%
YTD 89.5%
1Y 138.4%
3Y (2.7%)
5Y 49.9%
10Y (74.1%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
TLSA Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$109.6M
$108.7M
$0.0
($7,702.0K)
Shares Outstanding
102M
Employees
N/A
Growth (CAGR)
N/A
0.09%
10.5%
Profitability
Intrinsic Value
$1.0 (6.3% overvalued)
N/A
$1.0
N/A
Valuation (LTM)
Return on Capital
(115.6%)
(73.5%)
(245.0%)
(105.0%)
(656.6%)
1,014.6%
1,014.6%
Financial Health
$1,183.0K
($936.0K)
0.1x
(1,434.3x)
Dividends
Earnings
Aug 19, 2022
MISS by 0.0%
MISS by 0.0%
37.5%
1 Beat & 9 Miss
TLSA Stock Financials
TLSA Income Statement Metrics
Annual
Quarterly
LTM
TLSA Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($15.7M) +478.6% YoY
Capital Expenditure (CAPEX)
$0.0 -100.0% YoY
Free Cash Flow (FCF)
($15.7M) +478.2% YoY
TLSA Income Statement Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Operating
expenses
$18.0M 23.3% YoY
TLSA Balance Sheet Overview
Annual
Quarterly
LTM
Dec'14
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$12.2M
Current assets ($7,337.0K, 60.2% of total)
$1,183.0K (9.7%)
$6,052.0K (49.7%)
Other current assets
$102.0K (0.8%)
Non-current assets ($4,847.0K, 39.8% of total)
$4,554.0K (37.4%)
$293.0K (2.4%)
$0.0 (0.0%)
Other non-current assets
$0.0 (0.0%)
Financial position
($936.0K)
Cash & Short-term
Investments
Total Debt
TLSA Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
TLSA Earnings Surprises
Crunching data... Almost there!
TLSA Dividends
TLSA Dividend Yield
Crunching data... Almost there!
TLSA Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with TLSA
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$109.6M | 4.5 | $1.0 6.3% overvalued | 138.4% | $0.0 | ($7,702.0K) | N/A | N/A | N/A | (245.0%) | 4.5% | |
$131.8B | 5.8 | $186.0 63.7% overvalued | 23.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$71.1B | 6.4 | $1,034.1 56.4% undervalued | (31.1%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$43.1B | 6.3 | $161.4 73.4% overvalued | 52.6% | $3,154.8M | ($58.8M) | 157.1% | (1.9%) | 74.8% | 67.0% | 0.7% | |
$37.4B | 5.2 | $92.7 68.1% overvalued | 91.2% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.2B | 6.0 | $193.7 92.5% undervalued | 8.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$15.1B | 5.5 | $68.9 104.3% undervalued | 14.9% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$15.0B | 6.0 | $0.6 97.2% overvalued | 530.8% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.3B | 7.8 | $542.3 69.6% undervalued | 31.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.7B | 6.8 | $50.8 29.4% overvalued | (16.8%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$1,846.9M | 5.5 | $2,609.6 1,051.1% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Tiziana Life Sciences Ltd (TLSA) stock rating?
As of today, Tiziana Life Sciences Ltd has a stock rating of N/A (out of 10), which is considered Great.
is Tiziana Life Sciences Ltd (TLSA) a good stock to buy?
As of today, Tiziana Life Sciences Ltd has a Great stock rating, which is N/A undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 12.8%.